Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Brown, J. R., Eichhorst, B. F., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Kaźmierczak, M., Jurczak, W., Zhou, K., Simkovic, M., Mayer, J., Gillespie-Twardy, A. L., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., Osterborg, A., … Shadman, M. (2023). Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL). Blood, 142(Supplement 1), 202–202. https://doi.org/10.1182/blood-2023-174289
Authors:
Jennifer R. Brown
Barbara Eichhorst
Nicole Lamanna
Susan O’Brien
Constantine S. Tam
Luqui Qiu
Maciej Kaźmierczak
Wojciech Jurczak
Keshu Zhou
Martin Šimkovič
Jiřı́ Mayer
Amanda Gillespie-Twardy
Alessandra Ferrajoli
Peter Ganly
Robert Weinkove
Sebastian Grosicki
Andrzej Mital
Tadeusz Robak
Anders Österborg
Habte Yimer
Megan Wang
Tommi Salmi
Liping Wang
Jessica Li
Kenneth Wu
Aileen Cleary Cohen
Mazyar Shadman
Affiliated Authors:
Nicole Lamanna
Columbia Affiliation:
Subjects:
Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1182/blood-2023-174289
DOI:
10.1182/blood-2023-174289
Journal:
Blood
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: